Hemantane
 | |
| Clinical data | |
|---|---|
| Other names | Hymantane; Gimantan; N-Adamant-2-ylhexamethyleneimine; N-(2-Adamantyl)hexamethyleneimine |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C16H27N |
| Molar mass | 233.399 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
Hemantane, or hymantane, also known as N-(2-adamantyl)hexamethyleneimine, is an experimental antiparkinsonian agent of the adamantane family that was never marketed.[1] It was developed and studied in Russia.[1]
It has been said to act as a low-affinity non-competitive NMDA receptor antagonist, as a selective MAO-B inhibitor, and as showing various other actions and effects such as modulation of the dopaminergic and serotonergic systems in the striatum.[1][2] The drug has also been theorized to be a sigma receptor agonist, which is said to likely be involved in its dopaminergic effects.[1] Analogues of hemantane, such as memantine and amantadine, share some of these actions, like NMDA receptor antagonism, sigma receptor agonism, and dopaminergic modulation.[1]
The drug was first described by 2000.[3][4]
The dosage of gimantan is standardized to 50mg tablet strength.[5]
Chemistry
Gimantan is synthesized, according to the Leuckart reaction, by heating adamantanone and azepane in the presence of formic acid.[6][7][8]
See also
References
- 1 2 3 4 5 Abaimov DA, Kovalev GI (2011). "Sigma receptors as a pharmacological target for neuroprotectors. New horizons of pharmacotherapy of Parkinson disease". Neurochemical Journal. 5 (2): 83–91. doi:10.1134/S1819712411010028. ISSN 1819-7124.
- ↑ Fischler PV, Soyka M, Seifritz E, Mutschler J (2022). "Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review". Frontiers in Pharmacology. 13 927703. doi:10.3389/fphar.2022.927703. PMC 9574013. PMID 36263121.
- ↑ Val'dman EA (2000). "[Pharmacological activity of the new adamantane derivative--potential antiparkinson preparation during subchronic administration]". Eksperimental'naia i Klinicheskaia Farmakologiia (in Russian). 63 (5): 3–6. PMID 11109514.
- ↑ Andiarzhanova EA, Val'dman EA, Kudrin VS, Raevskiĭ KS, Voronina TA (2001). "[Effect of the new potential anti-Parkinson agent, hymantane, on levels of monoamines and their metabolites in rat striatum (a microdialysis study)]". Eksperimental'naia i Klinicheskaia Farmakologiia (in Russian). 64 (6): 13–16. PMID 11871228.
- ↑ Tsvetkova EA, Volkova MY, Stepanenko OB, Kislyak NA, Shcherbakova OV, Avdyunina NI, et al. (January 2002). "Gimantan Tablets: Analysis and Standardization". Pharmaceutical Chemistry Journal. 36 (1): 48–50. doi:10.1023/A:1015761110991.
- ↑ Sergeeva MS, Grushevskaya LN, Pyatin BM, Avdyunina NI, Gaevaya LM, Klumova VS, et al. (November 2011). "Pharmaceutical analysis and standardization of gimantan parenteral dosage form". Pharmaceutical Chemistry Journal. 45 (8): 499–502. doi:10.1007/s11094-011-0664-1.
- ↑ Seredenin SB, Voronina TA, Avdyunina NI, Pyatin BM, Morozov IS, Bykov NP, et al. (2010). "SU1825499 "N-(2-adamantyl)hexamethyleneimine hydrochloride with anticataleptic activity". Byull. Izobret. (in Russian). 4.
- ↑ Tsvetkova EA, Volkova MY, Stepanenko OB, Avdyunina NI, Bol'shakova RF, Pyatin BM (November 2001). "Analysis and Standardization of the New Domestic Antiparkinsonian Drug Gimantan". Pharmaceutical Chemistry Journal. 35 (11): 635–638. doi:10.1023/A:1015158213734.